Volume : 10, Issue : 02, February – 2023
Title:
02.QUALITY BY DESIGN (QbD) on CLINICAL TRIALS ACTIVITIES – A REVIEW
Authors :
Mr. V. S. Chandrasekaran, Miss. Syed Arshiya Sultana*, Dr. M. Kishore Babu
Abstract :
Pharmaceutical industry is constantly looking for ways to ensure and enhance product safety, quality and efficacy. However, drug recalls, manufacturing failure costs, scale up issues and regulatory burden in recent past suggest otherwise. In traditional quality by testing (QbT) approach, the product quality and performance are predominantly ensured by end product testing with limited understanding of the process and critical process parameters. Regulatory bodies are therefore focusing on implementing quality by design (QbD), a science-based approach that improves process understanding by reducing process variation and enabling process-control strategies. In this regards, pharmaceutical industry is currently undergoing a significant transformation to stream line their R&D process, provide greater manufacturing flexibility and control, and to reduce regulatory burden. However, there is a limited understanding and major concerns regarding the implementation of QbD principle in the pharmaceutical arena. The objective of this review article is therefore to provide a comprehensive understanding on various aspects of QbD, along with addressing the concerns related to its implementation.
KEYWORDS: Quality by Design, Design of experiment, Quality risk management, Design space, Quality target product profile.
Cite This Article:
Please cite this article in press V. S. Chandrasekaran et al, Quality By Design (QbD) On Clinical Trials Activities – A Review., Indo Am. J. P. Sci, 2023; 10(02).
Number of Downloads : 10
References:
1. Jyotsna Balasaheb jadhav1, Nithin Namdeo Girawale and Rakesh Ashok Chaudhari. Quality by design (QBD) Approach used in development of pharmaceuticals. ISSN:2320 -705. International Journal of Pure Applied Bio-science. 2(5): 214-223(2014).
2. Sushila D.chavan*,Nayana V. Pimpodkhar, Amrutha S.kadam, Puja S.Gaikwad. Research and Reviews: Journal of pharmaceutical Quality Assurance Quality by Design.
3. WHO Prequalification Programme: priority Essential Medicines Quality by Design (QBD) and Pharmaceutical Active Ingredient Manufacture. https://www.who.int/…/detail/prequalification-of-medicines-by-who
4. Miesta E. Source data verification: A quality control measure in clinical trials . clinical Leader. August 2015.
5. Sprenger S,Nickerson D Meeker-O’connell A, Morrision B. Quality by design in clinical trials : A Collaborative pilot with the FDA .Therapeutic Innovative Regulatory science.2012;47(2):161-6.
6. G.Kaur, R.L.Smyth ,C .V .Powell,P.Williamson A survey of facilitators and barriers to recruitment to the MAGNETIC trial Trials ,17 (1)(2016),Article607C.
7. Macefield ,A.D.Beswick ,J.M. Blazeby,J.A Lane A systematic review of on -site monitoring methods for health-care randomised controlled trials,10(1)(2013),pp.104-124
8. Kenett R S, Kenett D A. Quality by Design applications in biosimilar pharmaceutical products. Accreditation and Quality Assurance, springer verlag, NY, 13:681-690,2008.
9. Trivedi B. Quality by Design (QBD) In pharmaceuticals. International Journals of pharmacy and pharmaceutical sciences ,4(1):17-29,2012.
10. Patil A S, Pethe A M Quality by Design (QBD): A New concept for development of quality pharmaceuticals Quality Assurance, 4(2):13-19.2013
11. Lawrence X Y ,Robert L,Michael C ,Olson GJ,Gary B, Helen W.Quality by design for generic drugs .Pharmaceutical Technology ,33(10):122-127,2009.
12. Kourti T , Davis B. The business benefits of Quality by Design. Pharmaceutical engineering ,32(4):1-10,2012.